NCT05761171 2026-04-21
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Children's Oncology Group
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT06317662 2026-04-16
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03959085 2026-03-31
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
Phase 3 Recruiting
NCT04872790 2026-02-10
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
OHSU Knight Cancer Institute
Phase 1 Recruiting
NCT04440267 2025-08-06
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting